Gilead Sciences, Inc. (GILD)

The firm pointed to Gilead Sciences trading at 13 times next year earnings. HSBC said this multiple makes the stock appealing given the growth opportunities. The stock currently trades at a P/E ratio of 17.71 with a PEG ratio of just 0.32, suggesting strong value relative to growth.

Gilead trades at about 17.9 times earnings. Analysts maintain a Buy consensus rating with an average price forecast of $161.23, according to data from 23 analysts. Recent rating actions include: Cantor Fitzgerald: Reiterated Overweight, maintained a $155 price forecast on July 6. HSBC: Upgraded the …

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination …

In late June 2026, Gilead Sciences reported that the FDA and European Commission approved Trodelvy for first-line treatment of unresectable locally advanced or metastatic triple-negative breast cancer, backed by Phase 3 ASCENT-03 and ASCENT-04 data showing clinically meaningful progression-free ...

Calendar & Research Financial Calendar Earnings Calendar & Reports Analyst Ratings Fund Letters Archive Transcripts Search Stock Market Holidays ... On July 06, 2026, Gilead Sciences Inc GILD announced its involvement in a clinical trial aimed at treating patients infected with the Bundibugyo ...